Cerevel Therapeutics Holdings Inc
(NAS:CERE)
$
44.96
0 (0%)
Market Cap: 8.19 Bil
Enterprise Value: 7.71 Bil
PE Ratio: 0
PB Ratio: 14.49
GF Score: 20/100 Cerevel Therapeutics Holdings Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023 / 01:30PM GMT
Release Date Price:
$23.45
(-2.45%)
Jeff Hung
Morgan Stanley, Research Division - Equity Analyst
Welcome to the Morgan Stanley Global Healthcare Conference. I'm Jeff Hung, one of the biotech analyst. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. For this session, we have Ron Renaud, CEO of Cerevel Therapeutics. Welcome, Ron.
Ronald C. Renaud
Cerevel Therapeutics Holdings, Inc. - President, CEO & Director
Thanks for having me.
Jeff Hung
Morgan Stanley, Research Division - Equity Analyst
For those who may not be familiar with Cerevel, can you provide a brief introduction?
Ronald C. Renaud
Cerevel Therapeutics Holdings, Inc. - President, CEO & Director
Sure. So Cerevel is a company that was really born inside of Pfizer and was spun out a
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot